Design of a phase 2b randomized clinical trial (ENDEAVOR) to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in HF with preserved and mildly reduced EF
Topic:
Trial Design
Speaker:
Professor L. Lund (Stockholm, SE)
Event:
Heart Failure 2023
Congress Presentation
2 more presentations in this session
Access the full session
About the event
